Assessment of local control, survival outcome and late toxicities of patients treated with hypofractionated radiotherapy in locally advanced cancer of the uterine cervix- Longitudinal descriptive study.
Phase 2
- Conditions
- Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
- Registration Number
- CTRI/2021/04/032732
- Lead Sponsor
- JIPMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patiets with histologically (squamous and adenocarcinoma ) proven cancer of the uterine cervix stage Ib to IVa
2. Karnofsky Performance Score >50
3. Creatinine clearance <50 ml/min
4. Patients treated with hypofractionated External Beam radiotherapy of 45Gy in 20 fractions with midline shielding without chemotherapy, followed by standard intracavitary brachytherapy 8.5 Gy in three fractions each in the department since 2016
Exclusion Criteria
1. History of chemotherapy or radiation to abdomen or pelvis.
2. Tumour involving lower third of vagina
3. History of other cancers
4. Expected survival less than 3 months
5. Pregnant women
6. Patients who were FIGO Stage IVB at diagnosis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method